These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 20306214

  • 1. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients.
    Madsen OR, Rytter A, Hansen LB, Suetta C, Egsmose C.
    Clin Rheumatol; 2010 Aug; 29(8):849-54. PubMed ID: 20306214
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [Abstract] [Full Text] [Related]

  • 3. Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.
    Lin Z, Gu J, He P, Gao J, Zuo X, Ye Z, Shao F, Zhan F, Lin J, Li L, Wei Y, Xu M, Liao Z, Lin Q.
    Rheumatol Int; 2011 Feb; 31(2):233-8. PubMed ID: 20012866
    [Abstract] [Full Text] [Related]

  • 4. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
    Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL, BSR Biologics Register.
    Rheumatology (Oxford); 2010 Mar; 49(3):563-70. PubMed ID: 20032223
    [Abstract] [Full Text] [Related]

  • 5. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
    Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML.
    Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
    [Abstract] [Full Text] [Related]

  • 6. Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
    Madsen OR.
    Rheumatol Int; 2018 Mar; 38(3):425-432. PubMed ID: 29299630
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the Iranian versions of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Patient Acceptable Symptom State (PASS) in patients with ankylosing spondylitis.
    Bidad K, Fallahi S, Mahmoudi M, Jamshidi A, Farhadi E, Meysamie A, Nicknam MH.
    Rheumatol Int; 2012 Nov; 32(11):3613-8. PubMed ID: 22101612
    [Abstract] [Full Text] [Related]

  • 8. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G).
    Jones SD, Steiner A, Garrett SL, Calin A.
    Br J Rheumatol; 1996 Jan; 35(1):66-71. PubMed ID: 8624626
    [Abstract] [Full Text] [Related]

  • 9. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 10. Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis.
    Rostom S, Benbouaaza K, Amine B, Bahiri R, Ibn Yacoub Y, Ali Ou Alla S, Abouqal R, Hajjaj-Hassouni N.
    Clin Rheumatol; 2010 Jul; 29(7):781-8. PubMed ID: 20383548
    [Abstract] [Full Text] [Related]

  • 11. Translation, cultural adaptation, and validation of the Bath questionnaires and HAQ-S in Hindi for Indian patients with ankylosing spondylitis.
    Dhir V, Kulkarni S, Adgaonkar A, Dhobe P, Aggarwal A.
    Clin Rheumatol; 2012 Oct; 31(10):1511-5. PubMed ID: 22829065
    [Abstract] [Full Text] [Related]

  • 12. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [Abstract] [Full Text] [Related]

  • 13. Development of a Bangla version of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI).
    Abdal SJ, Yesmin S, Shazzad MN, Azad MAK, Shahin MA, Choudhury MR, Islam MN, Haq SA.
    Int J Rheum Dis; 2021 Jan; 24(1):74-80. PubMed ID: 33135389
    [Abstract] [Full Text] [Related]

  • 14. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J, Sieper J, Weiß A, Zink A, Listing J.
    Ann Rheum Dis; 2015 Jun 19; 74(6):1241-8. PubMed ID: 24718959
    [Abstract] [Full Text] [Related]

  • 16. Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies.
    Cardiel MH, Londoño JD, Gutiérrez E, Pacheco-Tena C, Vázquez-Mellado J, Burgos-Vargas R.
    Clin Exp Rheumatol; 2003 Jun 19; 21(4):451-8. PubMed ID: 12942696
    [Abstract] [Full Text] [Related]

  • 17. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.
    Arthritis Res Ther; 2011 Jun 20; 13(3):R94. PubMed ID: 21689401
    [Abstract] [Full Text] [Related]

  • 18. The Swedish version of the Bath ankylosing spondylitis disease activity index. Reliability and validity.
    Waldner A, Cronstedt H, Stenström CH.
    Scand J Rheumatol Suppl; 1999 Jun 20; 111():10-6. PubMed ID: 10503554
    [Abstract] [Full Text] [Related]

  • 19. [Validation of the Italian versions of the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Dougados Functional Index (DFI) in patients with ankylosing spondylitis].
    Salaffi F, Stancati A, Silvestri A, Carotti M, Grassi W.
    Reumatismo; 2005 Jun 20; 57(3):161-73. PubMed ID: 16258600
    [Abstract] [Full Text] [Related]

  • 20. Validity of a Venezuelan version of the Bath Ankylosing Spondylitis Functional Index and Bath Ankylosing Spondylitis Disease Activity Index.
    Rauseo Vera M, Gutiérrez-González LA, Maldonado I, Al Snih S.
    Reumatol Clin (Engl Ed); 2019 Jun 20; 15(4):223-228. PubMed ID: 28943073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.